AdAlta has issued an initial public offering (IPO) on the Australian Stock Exchange to raise AU $10 million (US…
Articles by Inês Martins, PhD
A biochemical pathway in the lungs, in which an antioxidant called glutathione (GSH) binds to and changes the nature of specific proteins, may…
Two clinical hallmarks of patients with idiopathic pulmonary fibrosis (IPF), traction bronchiectasis and honeycombing, may be aspects of one continuous process…
The U.S. Patent and Trademark Office issued a new patent to iBio, covering the company’s rights for the use of endostatin-related…
Patient stratification to deliver personalized medicine has become a routine practice in oncology that may be of great help in understanding…
Doctors rarely see patients with symptoms of both pulmonary fibrosis and emphysema, but those who do quickly learn that these patients chart a…
Bellerophon Therapeutics recently announced that the Phase 3 INOvation-1 clinical trial evaluating the safety and efficacy of the INOpulse delivery…
Circulating levels of two biomarkers — matrix metalloproteinase-7 (MMP-7) and Krebs von den Lungen-6 (KL-6) — may be effective predictors of…
Auto-immunity may have a role in the development of fibrotic idiopathic interstitial pneumonias (fIIP), a disease once thought to result…
Patients with idiopathic pulmonary fibrosis (IPF) often exhibit cardiovascular manifestations that affect patients’ morbidity and mortality according to the study”…